Matthew Johnson, DO
Physical Medicine & Rehabilitation · Orange, CANPI 1013199124
Payments from drug & device makers
Across 162 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$269
- AbbVie$253
- Amgen$201
- Pfizer$161
- Daiichi Sankyo Inc.$143
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$143
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 16 | $269 |
| AbbVie(2 entities) | 12 | $253 |
| Amgen | 20 | $201 |
| Pfizer | 22 | $161 |
| Daiichi Sankyo Inc. | 16 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $143 |
| Biohaven Pharmaceuticals, Inc. | 5 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $118 |
| Electronic Waveform Lab, Inc. | 4 | $92 |
| Redhill Biopharma Inc. | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 3 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| GRT US Holding, Inc. | 3 | $71 |
| Abbott | 3 | $68 |
| IBSA Pharma Inc. | 4 | $59 |
| Vertos Medical, Inc. | 2 | $57 |
| Scilex Pharmaceuticals Inc. | 3 | $56 |
| Nevro Corp. | 2 | $54 |
| Relievant Medsystems, Inc. | 2 | $48 |
| Novartis | 2 | $42 |
| Bioventus LLC | 2 | $34 |
| Si-bone, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $33 |
| Almatica Pharma LLC | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| Biodelivery Sciences International, Inc. | 2 | $26 |
| Vertiflex, Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
How this compares
$2,490 in reported general payments places this provider in the 80th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 20 | $162 |
| Gabapentin | 18 | $128 |
| Nortriptyline Hcl | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Orange
- David MajorsOrange$51K
- Ziyad AyyoubParamount$1.8M
- John ShenFontana$1.3M
- Andrew SkalskySan Diego$463K
- Nanette JoyceSacramento$237K
- Mary OatesSanta Maria$158K
- Jeryl WiensFresno$125K
- Pratik GandhiAnaheim$122K
- Ronald SchillingLong Beach$113K
- Kevin BarretteSan Francisco$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.